Nestor Iván Gómez Goicochea

Nestor Iván Gómez Goicochea

Auto-generated profile, based on publicly available information

Nestor Iván Gómez Goicochea

School of Medicine, Universidad Cesar Vallejo, Trujillo, Peru

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2024 in International Journal of Nephrology and Renovascular Disease
Verified
Journal Article
Open access
PDF file
EGEvelyn Del Socorro Goicochea-Rios
Evelyn Del Socorro Goicochea-Rios
IYIrma Luz Yupari-Azabache
Irma Luz Yupari-Azabache
NGNelida Milly Esther Otiniano García
Nelida Milly Esther Otiniano García
NGNéstor Iván Gómez Goicochea
Néstor Iván Gómez Goicochea
Introduction: Chronic kidney disease affects the quality of life of people with diabetes mellitus, increases cardiovascular risk, and has high social costs. Objective: To determine associated factors for chronic kidney disease in people with diabetes mellitus type 2. Material and Methods: Retrospective cohort study with 371 patients evaluated in primary care for diabetes mellitus. Information on age, sex, disease duration, comorbidity and laboratory results was obtained. Patients of both sexes attended between 2022 and 2024 were included. Patients with other renal diseases or referrals were excluded. Logistic regression analysis was performed to identify associated factors. Results: Males (p = 0.014), age > 60 years, (p = 0.01) uncontrolled diabetes (HbA1C > 7.99%± 1.84) and disease duration over 20 years (p = 0.02) are associated factors for chronic kidney disease (CKD). HbA1c had significant differences between those with and those without CKD. The most frequent comorbidities are arterial hypertension (70%), dyslipidemia (43%), overweight/obesity (44%) and anemia (31%). CKD stage G2 is the most frequent (45%). One hundred percent of patients in G1 and G2 CKD stages have an elevated microalbuminuria/creatinuria rate, and 13% of patients between G3a and G4 stages have this rate within normal values. Most patients receive nephroprotection with ARA II and ACEIs. Conclusion: It is important to screen for kidney disease in patients with diabetes mellitus type 2 who are male, over 60 years of age, with uncontrolled HbA1c and prolonged disease duration, as well as to treat comorbidities and nephroprotection regardless of the stage of chronic kidney disease.

1 March 2024 in International Journal of Nephrology and Renovascular Disease
Verified
Journal Article
Open access
PDF file
EGEvelyn Goicochea-Rios
Evelyn Goicochea-Rios
ACAna Chian-García
Ana Chian-García
IYIrma Luz Yupari-Azabache
Irma Luz Yupari-Azabache
NGNéstor Gómez Goicochea
Néstor Gómez Goicochea
Introduction: Chronic kidney disease affects a large part of the population with hypertension, diabetes mellitus as well as those over 50 years of age. Research reported that male sex and other comorbidities such as obesity and anemia are more frequent in Chronic kidney disease, as well as uncontrolled diabetes mellitus or hypertension. Objective: To determine the risk factors associated with the development of chronic kidney disease in adults with arterial hypertension. Material and Methods: Retrospective cohort study of 455 patients with hypertension treated in a primary health care hospital. Medical records and laboratory information were reviewed for the diagnosis of chronic kidney disease and its staging. Patients aged 40 years and older, of both sexes and evaluated between the years 2015 − 2017 were included. Logistic regression analysis allowed the identification of risk factors associated with the development of chronic kidney disease. Results: 63.7% were female and 36.3% male. The average age for 2015 was 69.79 ± 9.03, more than half of participants had diabetes mellitus and controlled hypertension and the predominant nephroprotection was with Losartan (53%) that year. Male sex (OR 1.68, CI 1.03– 2,76), age: 60 years or older (OR 6.38, CI 2.65– 15,37) and anemia (OR 1.71, CI 1.03– 2,85), were risk factors for the development of chronic kidney disease (p < 0.05), whereas nephroprotection (OR 0.39, CI 0.18– 0,88) and controlled diabetes mellitus (OR: 0.18, CI 0.07– 0,47) were shown to be protective factors (p < 0.05). The prevalence of chronic kidney disease between 2015 and 2017 was 19% and 45%, respectively, with predominance of category G2. The comparison group is the same cohort analyzed in each year under study. Conclusion: Male sex, age over 60 years, and anemia are risk factors for chronic kidney disease. Nephroprotection, controlled diabetes mellitus, and patient follow-up are factors that prevent its development.

7 September 2022 in Revista de la Facultad de Medicina Humana
Verified
Journal Article
Open access
PDF file
EGEvelyn Goicochea-Ríos
Evelyn Goicochea-Ríos
OSOfelia M. Córdova Paz Soldán
Ofelia M. Córdova Paz Soldán
NGNéstor I. Gómez Goicochea
Néstor I. Gómez Goicochea
JVJessica Vicuña Villacorta
Jessica Vicuña Villacorta
Objectives: To identify post COVID-19 sequelae in patients with medical discharge for this pathology. Methods: A prospective descriptive study was conducted between the second and fourth quarter of 2021 with a population of 330 patients diagnosed with COVID-19. Baseline was established at the beginning of the study, followed by follow-up and control consultation to identify post-COVID-19 sequelae and to perform control spirometry. Results: The frequency of COVID-19 was 29.78% (330 cases/1108 attended). The 43.94% of positive cases were in the 40-59 years age group, 28.8% (95/330) referred as comorbidity: cardiovascular disease, diabetes mellitus II and bronchial asthma. Post COVID-19 sequelae predominated: respiratory (61%), musculoskeletal (43%) and neurological (20%), with dyspnea, dorsalgia and headache, respectively. The duration of sequelae ranged from 21 days to seven months, spirometry showed a mild restrictive pattern in patients aged 41 to 50 years, all female. Conclusions: It is important to identify post-COVID-19 sequelae for treatment to recover the integral health of individuals.

15 March 2024 in Revista Española de Educación Médica
Verified
Journal Article
Open access
PDF file
EGEvelyn Goicochea-Ríos
Evelyn Goicochea-Ríos
NGNelida Milly Esther Otiniano García
Nelida Milly Esther Otiniano García
AGAna María Chian García
Ana María Chian García
NGNestor Iván Gómez Goicochea
Nestor Iván Gómez Goicochea
JVJessica Ericka Vicuña Villacorta
Jessica Ericka Vicuña Villacorta
Revista Española de Educación Médica